TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01702155
Drug: DFP-10917
Normalized name: DFP
DrugBank: Isoflurophate (DB00677)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04397276
Drug: JNJ-70218902
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-70218902 will be administered.
Study: NCT04641234
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As prescribed by the treating physician
Study: NCT00469352
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab as needed
Study: NCT02173756
Drug: morphine gel
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg / ml ofmorphine hydrochloride, presented in a 5 mL sterile syringe (single dose), raspberry aroma, 30% glucose
Study: NCT00124644
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00124644
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00124644
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00124644
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03669965
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib per approved prescribing label
Study: NCT00692757
Drug: Hypochlorous acid
Normalized name: Hypochlorous acid
DrugBank: Hypochlorous acid (DB14135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypochlorous acid for preoperative scrubbing to prevent surgical site infection in spray
Study: NCT00692757
Drug: Iodopovidone
Normalized name: Iodopovidone
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodopovidone
Study: NCT04344236
Drug: 0.5% Povidone/Iodine oral/nasal rinse
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
Study: NCT04344236
Drug: 0.12% Chlorhexidine oral/nasal rinse
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
Study: NCT01182272
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00315042
Drug: Penicillin
Normalized name: Penicillin
DrugBank: Nafcillin (DB00607)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00458575
Drug: CNTO 2476
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant 1 will receive 5.6x100000; Participants 2, 3, 5, 6, and 7 will receive 6.0x10000; Participant 4 will receive 3.0x100000; and Participants 8 and 9 will receive 1.2x100000 of CNTO 2476 as a single dose of viable cells in phosphate buffered saline (PBS) in a total volume of 100 μL injected subretinally.
Study: NCT06504888
Drug: Penicillin
Normalized name: Penicillin
DrugBank: Nafcillin (DB00607)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compare whether there is a higher incidence of sinus elevation in patients allergic to penicillin compared to non-allergic patients, evaluating clinical histories.
Study: NCT03525782
Drug: PD-1 mAb
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with an identical course with a FDA approved monoclonal antibody against PD-1
Study: NCT04012307
Drug: Candesartan Cilexetil 32mg
Normalized name: CANDESARTAN CILEXETIL 32MG TAB
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan Cilexetil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 32 mg of candesartan cilexetil.
Study: NCT04528680
Drug: Chemotherapy, albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion of ABX over 30 minutes
Study: NCT04528680
Drug: Chemotherapy, carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion of carboplatin over 30 minutes
Study: NCT00308113
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 0/75 mg/kg/day.
Study: NCT05308342
Drug: hormone replacement treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine estrogen progesterone replacement periodic therapy
Study: NCT03313544
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NIVOLUMAB
Study: NCT01596699
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 mg/kg (max 15 mg or max 6 mg), IV, Day -12 to Day -10 pre-HCT
Study: NCT01596699
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.8 mg/kg/dose q6hrs or 1.1 mg/kg/dose q6hrs, IV, Day -9 to Day -6 pre-HCT
Study: NCT01596699
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2 or 1.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
Study: NCT01596699
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg/m2 or 0.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
Study: NCT00002371
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002371
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002371
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002371
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00090558
Drug: nitroglycerin
Normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01935128
Drug: Arm 1 Everolimus/Reduced dose tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunosuppression drug intervention
Study: NCT00911586
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01550107
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg b.d for 24 weeks
Study: NCT02799745
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT00329498
Drug: L-Ascorbic Acid
Normalized name: L-ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00019019
Drug: carboxyamidotriazole
Normalized name: Carboxyamidotriazole
DrugBank: Carboxyamidotriazole (DB11960)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00019019
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00961298
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will receive single-blind placebo for the first two weeks, and then duloxetine for the next 12 weeks, followed by an up to 2 week taper off of the duloxetine. After 2 weeks of placebo daily, subjects will receive 30 mg per day of duloxetine for two weeks, then titrated up to 60 mg per day of duloxetine at week 2. A dosage decrease to 30 mg daily is permittable after week 2. This will be a flexible dose study with doses of duloxetine progressively increasing at weeks 4 (90 mg daily) and 6 (120 mg daily) in conjunction with CGI-I scores, to reach 120 mg daily or the maximum tolerated dose, if less than 120 mg daily at Week 12. There will be a post-taper follow up appointment at Week 14. Of Note: Amendment IRB Approved 6/14/11 Study Ending at Week 12 with removal of Week 14 visit as part of study.
Study: NCT01857362
Drug: Nitisinone 20 mg
Normalized name: nitisinone 20 MG
DrugBank: Nitisinone (DB00348)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nitisinone 20 mg capsules
Study: NCT01857362
Drug: Nitisinone 10 mg
Normalized name: nitisinone 10 MG
DrugBank: Nitisinone (DB00348)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nitisinone 10 mg capsules
Study: NCT01961453
Drug: Isosorbide Mononitrate, sustained release
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2
Study: NCT01178814
Drug: Revlimid (Lenalidomide)
Normalized name: lenalidomide Oral Capsule [Revlimid]
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.
Study: NCT02534129
Drug: Aquaphor
Normalized name: Aquaphor
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquaphor is applied to one half of radiation field
Study: NCT01100268
Drug: Methylphenidate ER
Normalized name: Methylphenidate Hydrochloride 20 MG Oral Tablet, Extended Release [METHYLPHENIDATE ER]
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
Study: NCT03154827
Drug: BL-8040
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive maintenance treatment consisting of subcutaneous (SC) injections of BL-8040 on Days 1, 2 and 3 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
Study: NCT04402359
Drug: meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: meropenem one gram slowly IV infusion every 8 hours for 14 days
Study: NCT03154827
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive maintenance treatment consisting of intravenous (IV) infusion of Atezolizumab on Day 2 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
Study: NCT03840200
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib will be administered orally.
Study: NCT03840200
Drug: Rucaparib
Normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rucaparib will be administered orally.
Study: NCT01755247
Drug: Topical Gel Vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04402359
Drug: ceftazidime 2 grams and avibactam 500
Normalized name: avibactam
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution).
Study: NCT01357447
Drug: Dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 2.5 mg solution BID via nebuliser for 2 weeks
Study: NCT01357447
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
Study: NCT00060268
Drug: HPPH
Normalized name: HPPH
DrugBank: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (DB15243)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv
Study: NCT03760458
Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food
Study: NCT03760458
Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed-dose combination immediate release tablets containing 600 mg ABC, 50 mg DTG, and 300 mg 3TC; administered orally once daily with or without food
Study: NCT03039608
Drug: combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local steroid injection and oral steroid
Study: NCT03039608
Drug: oral steroid administration（prednisone）
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral steroid
Study: NCT00750919
Drug: esmirtazapine
Normalized name: Esmirtazapine
DrugBank: Esmirtazapine (DB06678)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02290379
Drug: TNX-201 35 mg
Normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: TNX-201 35 mg
Study: NCT02290379
Drug: TNX-201 70 mg
Normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: TNX-201 70 mg
Study: NCT02290379
Drug: TNX-201 140 mg
Normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: TNX-201 140 mg
Study: NCT02290379
Drug: Racemic isometheptene 70 mg
Normalized name: isometheptene
DrugBank: Isometheptene (DB06706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator: Racemic isometheptene 70 mg
Study: NCT04599855
Drug: Esketamine 56 mg
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 56 mg will be self administered as nasal spray.
Study: NCT04599855
Drug: Esketamine 84 mg
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 84 mg will be self administered as nasal spray.
Study: NCT01544192
Drug: α-tocopherol
Normalized name: d-α-tocopherol
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x300 mg α-tocopherol
Study: NCT01980498
Drug: Physician choice-Usual care (PC-UC)
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The PC-UC will be started at a dose according to the physician choice. If this dose of PC-UC is effective on pain control, at the following meal the patient will take the same dose of PC-UC.~If the dose of PC-UC results non effective on pain control, at the following meal the patient will take an increased dose of the same PC-UC drug or change the PC-UC drug, according to the physician choice.
Study: NCT00255320
Drug: VIP
Normalized name: VIP
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00776620
Drug: Glimepiride 1mg Tablets
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01232374
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg (4 bottles), once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
Study: NCT01232374
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
Study: NCT01869569
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
Study: NCT02147067
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine 1,000 mg twice daily
Study: NCT00195494
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 \& 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2
Study: NCT04568304
Drug: Gemcitabine Hydrochloride for Injection
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000mg/㎡ iv infusion, on Day 1 and Day 8 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles.
Study: NCT04568304
Drug: Cisplatin for Injection / Carboplatin Injection
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 70mg/㎡ iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~Carboplatin AUC 4.5 iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles.
Study: NCT02762500
Drug: LYC-30937-EC
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01350102
Drug: Bacitracin
Normalized name: Bacitracin
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.
Study: NCT00158886
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan will be provided as capsules for oral administration and will be administered at least 3 hours before radiation therapy.
Study: NCT05465278
Drug: Alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 18 months treatment with alirocumab
Study: NCT00372099
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal salmon calcitonin 200UI/day during 2 years
Study: NCT04613219
Drug: Tofacitinib 5 MG [Xeljanz]
Normalized name: tofacitinib 5 MG [Xeljanz]
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with Tofacitinib
Study: NCT03717168
Drug: Recombinant human growth hormone
Normalized name: Recombinant human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patients received subcutaneous rHGH (0.3 IU/kg/ twice daily) for 10 days in addition to intensive care standard management.
Study: NCT00088816
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00088816
Drug: tegafur-gimeracil-oteracil potassium
Normalized name: tegafur
DrugBank: Oteracil (DB03209)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT04165096
Drug: diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO
Study: NCT00076115
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02640807
Drug: Interleukin-7
Normalized name: interleukin-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM (intra-muscular) administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR (International Normalized Ratio) \>2.5 or platelet count \< 35,000
Study: NCT00778141
Drug: metformin HC1 750 mg extended-release tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00515112
Drug: AndroGel
Normalized name: AndroGel
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Androgel 1%, 10g daily
Study: NCT00214318
Drug: Terbutaline plus Metoprolol or carvedilol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03074032
Drug: ONC1-0013B
Normalized name: Dna (recombinant vaccinia virus strain livp clone gl-onc1)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC1-0013B per os daily
Study: NCT01502787
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
Study: NCT00023400
Drug: Nelfinavir
Normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00023400
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02167451
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00198419
Drug: Vitrase
Normalized name: Vitrase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00766909
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.155 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 4 mg/kg 2 times daily for 8-11 days.